DynPort Vaccine said today it was awarded an indefinite delivery/indefinite quantity (IDIQ) contract valued at up to $159 million over 10 years toward managing medical product development initiatives for the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

DynPort, a wholly owned subsidiary of CSRA, said it was one of four awardees of the IDIQ contract, intended to support the development of new therapies to treat infectious diseases.

Work to be covered by the contract, DynPort said, will include developing manufacturing processes and analytical test methods, performing product characterization, conducting cGMP manufacturing, and providing regulatory services.

DynPort president Gary S. Nabors, Ph.D., said in a statement that his company has successfully conducted product development for government agencies for nearly 20 years.

The project will be funded with federal funds from NIAID under contract no. HHSN272201600005I.

IDIQ contracts provide for an indefinite quantity of services for a fixed time and are employed when a federal agency cannot determine, above a specified minimum, the precise quantities of supplies or services that it will require during the contract period.

Previous articlePrincipia Invests €4M in Human Tissue Drug Discovery Firm AnaBios
Next articleCapnia, Essentialis to Merge, With Focus on Rare Disease Treatments